Oncology News

Atezolizumab in combination with bevacizumab delayed time to deterioration of quality of life, physical functioning and role functioning compared with standard-of-care sorafenib as first-line treatment for unresectable hepatocellular carcinoma, according to patient-reported outcomes of the randomized phase 3 IMbrave 150 study scheduled for presentation at Gastrointestinal Cancers Symposium.

The FDA granted orphan drug designation to durvalumab and tremelimumab for treatment of patients with advanced hepatocellular carcinoma.

CStone Pharmaceuticals and Blueprint Medicines Corporation announced the first patient dosed in a phase 1b/2 trial of fisobatinib in combination with CS1001 for the treatment of locally advanced or metastatic hepatocellular carcinoma, according to a press release.

The PAGE-B score and a modified PAGE-B score identified which patients on antiviral therapy for chronic hepatitis B had a low risk for hepatocellular carcinoma development, according to published data.

Diets consisting of higher vegetable fat and polyunsaturated fat intake correlated with a lower risk for hepatocellular carcinoma, including cases in which individuals replaced other animal, dairy, or saturated fats with vegetable and polyunsaturated fats, according to data.

The American College of Gastroenterology released a new guideline on disorders of the mesenteric, portal, and hepatic veins and mesenteric and hepatic arteries, which can lead to acute liver failure, chronic liver disease, noncirrhotic portal hypertension, cirrhosis, and hepatocellular carcinoma.

In 2018, infections were the cause of 13% of all new cancer diagnoses, totaling 2.2 million new cases worldwide, although these totals do not include nonmelanoma skin cancers, according to findings published in The Lancet Global Health.

Nonenhanced MRI showed promise as an option for hepatocellular carcinoma surveillance in high-risk patients based on high-performance results with a short scan time and lack of contrast agent-associated risks, according to a study published in Journal of Hepatology.

Treatment with transarterial chemoembolization and Nexavar improved progression-free survival compared with transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma, according to a study published in Gut.

Treatment with Doptelet was cost-effective for the treatment of thrombocytopenia in patients with chronic liver diseases compared with other treatment options, according to data presented at the American Society of Hematology meeting.